Anna Ma

659 total citations
8 papers, 381 citations indexed

About

Anna Ma is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Anna Ma has authored 8 papers receiving a total of 381 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Oncology and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Anna Ma's work include Histone Deacetylase Inhibitors Research (6 papers), Protein Degradation and Inhibitors (5 papers) and CAR-T cell therapy research (3 papers). Anna Ma is often cited by papers focused on Histone Deacetylase Inhibitors Research (6 papers), Protein Degradation and Inhibitors (5 papers) and CAR-T cell therapy research (3 papers). Anna Ma collaborates with scholars based in United States, South Korea and Spain. Anna Ma's co-authors include Manish R. Patel, Kevin R. Kelly, Yasuhiro Oki, Anas Younes, Ian W. Flinn, David Tuck, Sattva S. Neelapu, Jesús G. Berdeja, Amanda Copeland and John F. Gerecitano and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Anna Ma

8 papers receiving 376 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Ma United States	5	254	159	79	47	47	8	381
Jennifer Kimberly Lue United States	11	244 1.0×	146 0.9×	170 2.2×	36 0.8×	94 2.0×	40	435
Thomas Mehrling United Kingdom	7	132 0.5×	81 0.5×	70 0.9×	73 1.6×	33 0.7×	22	258
Haig Inguilizian United States	5	190 0.7×	83 0.5×	103 1.3×	51 1.1×	30 0.6×	5	329
Joseph Castillo United States	5	131 0.5×	115 0.7×	115 1.5×	21 0.4×	62 1.3×	6	299
Matthias Reule United Kingdom	6	167 0.7×	103 0.6×	22 0.3×	36 0.8×	25 0.5×	11	273
Rachel Neuwirth United States	9	297 1.2×	169 1.1×	59 0.7×	52 1.1×	17 0.4×	12	419
Lucy Scott United Kingdom	5	253 1.0×	165 1.0×	111 1.4×	14 0.3×	27 0.6×	8	355
Stephanie K. Guest United Kingdom	7	323 1.3×	168 1.1×	65 0.8×	18 0.4×	19 0.4×	7	429
Maciej Szydłowski Poland	9	151 0.6×	102 0.6×	104 1.3×	37 0.8×	81 1.7×	34	313
Gary Simmons United States	9	144 0.6×	169 1.1×	37 0.5×	41 0.9×	31 0.7×	22	291

Countries citing papers authored by Anna Ma

Since Specialization

Citations

This map shows the geographic impact of Anna Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Ma more than expected).

Fields of papers citing papers by Anna Ma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Ma. The network helps show where Anna Ma may publish in the future.

Co-authorship network of co-authors of Anna Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Ma. A scholar is included among the top collaborators of Anna Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Ma. Anna Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Pal, Sumanta K., Melissa A. Reimers, Benjamin Garmezy, et al.. (2024). A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9–engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS2676–TPS2676. 4 indexed citations

Powderly, John D., Manish R. Patel, Jina Lee, et al.. (2017). CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study. Annals of Oncology. 28. v405–v406. 45 indexed citations

Oki, Yasuhiro, Kevin R. Kelly, Ian W. Flinn, et al.. (2017). CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial. Haematologica. 102(11). 1923–1930. 102 indexed citations

Younes, Anas, Jesús G. Berdeja, Manish R. Patel, et al.. (2016). Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. The Lancet Oncology. 17(5). 622–631. 156 indexed citations

Landsburg, Daniel J., et al.. (2016). Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients with MYC Alterations. Blood. 128(22). 5422–5422. 1 indexed citations

Younes, Anas, Jesús G. Berdeja, Manish R. Patel, et al.. (2015). Phase 1 Trial Testing Single Agent CUDC-907, a Novel, Oral Dual Inhibitor of Histone Deacetylase (HDAC) and PI3K: Initial Assessment of Patients with Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL), Including Double Expressor (DE) Lymphoma. Blood. 126(23). 257–257. 4 indexed citations

Shimizu, Toshio, Patricia LoRusso, K. Papadopoulos, et al.. (2014). Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 20(19). 5032–5040. 67 indexed citations

Wang, Jing, Anna Ma, Ruzanna Atoyan, et al.. (2013). CUDC-907, a Dual HDAC and PI3K Inhibitor, Potentially Targets Cancer Cells and The Microenvironment In Hematological Malignancies. Blood. 122(21). 4930–4930. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact